

1 **COMPARATIVE ANALYSIS OF ANTIBODY RESPONSES FROM COVID-19 CONVALESCENTS RECEIVING**
2 **VARIOUS VACCINES REVEALS CONSISTENT HIGH NEUTRALIZING ACTIVITY FOR SARS-CoV-2**
3 **VARIANT OF CONCERN OMICRON.**

4

5 Daniele Focosi^{1,#}, Massimo Franchini², Michael J. Joyner³, Arturo Casadevall⁴

6 ¹North-Western Tuscany Blood Bank, Pisa University Hospital, 56124 Pisa, Italy.

7 ²Division of Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy;

8 massimo.franchini@asst-mantova.it

9 ³Department of Anesthesiology & Perioperative Medicine, Mayo Clinic, Rochester, MN 55902, USA

10 joyner.michael@mayo.edu ;

11 ⁴Department of Medicine, Johns Hopkins School of Public Health and School of Medicine, Baltimore,

12 MD 21218, USA; acasade1@jhu.edu .

13 #corresponding author: via Paradisa 2, 56124 Pisa, Italy. E-mail: daniele.focosi@gmail.com

14 **Keywords:** COVID19; Omicron; convalescent plasma; vaccine; neutralizing antibodies; outpatients.

15 **Word count:** abstract 101; body 1478.

16 **Acknowledgements:** none.

17 **Funding Information:** none.

18 **Author contributions:** D.F. and M.J.J. conceived the manuscript; D.F. and M.F. analyzed the

19 literature; M.F. provided Figure 1; D.F. provided Figure 2; A.C. and M.J.J. revised the manuscript.

20

21

22 **Abstract**

23 The novel SARS-CoV-2 Omicron variant of concern (VOCs), with its escape from unboosted vaccines
24 and monoclonal antibodies, demonstrates the continued relevance of COVID19 convalescent plasma
25 therapies. Lessons learnt from previous usage of CCP suggests focusing on outpatients and using
26 high nAb-titer units in early disease stages. In this systematic analysis, we show that CCP from
27 unvaccinated donors is not effective against Omicron, while CCP from vaccinees convalescents from
28 previous VOCs or third-dose uninfected vaccinees is likely to remain effective against Omicron. CCP
29 remains the only antibody-based therapy that keeps up with the variants and provides an effective
30 tool to combat the emergence of variants that defeat monoclonal antibodies. Consequently, there is
31 a need for continue study of the variables that determine CCP efficacy.

32

33 Introduction

34 The SARS-CoV-2 Omicron variant of concern (VOC), named VUI-21NOV-01 by Public Health England
35 and belonging to GISAID clade GR/484A, was first reported on November 8, 2021 in South Africa
36 (particularly in Gauteng, North West and Limpopo regions, where it is likely to have been circulating
37 for weeks [1]), and shortly thereafter spread all around the world. Omicron mutations impact 27% of
38 T cell epitopes [2] and 31% of B cell epitopes of Spike, while percentages for other VOC were
39 significantly lower [3]. The omicron variant already includes several sublineages (with more expected
40 soon during such a massive spread), which are named by PANGO phylogeny using the BA alias: BA.1
41 (which represents the majority of cases) and BA.3 (a.k.a. 21K in NextStrain, both harboring the
42 HV69-70 deletion which leads to S-gene target failure in Thermo Fisher TaqPath® RT-PCR), and BA.2
43 (a.k.a. 21L in NextStrain).

44 The novel VOC Omicron is reducing the efficacy of all vaccines approved to date (unless 3 doses are
45 delivered) [4-19], represents an unexpected boost over CCP usage, with Omicron being treated as an
46 entirely novel virus instead of a SARS-CoV-2 variants. Two years into the pandemics, we are back to
47 the starting line for some therapeutic agents. Importantly, Omicron evades most monoclonal
48 antibodies (mAbs) approved to date [5,12-14,20,21] with the lone exception of sotrovimab:
49 nevertheless, as expected for non-cocktail mAb therapies, sotrovimab treatment-emergent immune
50 escape from S:E340K has been shown to be as high as 10% [22,23]. Despite the development of
51 promising oral small-chemical antivirals (molnupiravir and nirmatrelvir), the logistical and
52 economical hurdles for deploying these drugs worldwide will prevent their immediate availability.
53 COVID19 convalescent plasma (CCP) was used as a frontline treatment from the very beginning of
54 the pandemic. Efficacy outcomes have been mixed to date, with most failures explained by low dose
55 and late usage [24], but efficacy of high-titer CCP has been definitively proven in outpatients with
56 mild disease stages [25,26]. Neutralizing antibody (nAb) efficacy against variants of concerns (VOC)
57 remains a prerequisite to support CCP usage, which could now be collected also from vaccinated
58 convalescents including breakthrough infections [27]: pre-Omicron evidences suggest that those
59 nAbs have higher titers and are more effective against VOCs than those from unvaccinated
60 convalescents [28,29],

61 Several countries have up to 48 different possible vaccine schedules according to EMA and FDA
62 approvals including a number of homologous or heterologous boosts, but the most commonly
63 delivered in the westernized countries were 1) BNT162b2 and mRNA-1273 for 2 doses eventually
64 followed by a homologous boost; 2) ChAdOx1 for 2 doses eventually followed by a BNT162b2 boost;
65 3) Ad26.COVS.2 for 1 dose eventually followed by a BNT162b2 boost. Many more inactivated
66 vaccines have been in use in low-and-middle income countries, the ideal target regions for CCP
67 therapy, widen that this therapy is relatively inexpensive. All these patients can have received the
68 vaccine schedule before, after or without having been infected, and, further complicating the
69 picture, the nAb titer generally declines with time. Hence identifying the settings where the nAb titer
70 is highest will definitively increase the appropriateness of CCP collections. Variations in nAb titers
71 against a given SARS-CoV-2 strain are usually reported as fold-changes in geometric mean titer
72 (GMT) compared to wild-type strains: nevertheless, fold-changes for groups that include non-
73 responders can lead to highly artificial results and possibly over-interpretation. Rigorous studies
74 have hence reported the percentage of responders as primary outcome and provided fold-changes
75 of GMT where calculation is reasonable (100% responders in both arms) [19].

76 To date the most rigorous data repository for SARS-CoV-2 sensitivity to antivirals is the Stanford
77 University Coronavirus Antiviral & Resistance Database, but as of December 22, 2021 the tables
78 there summarizing “Virus Variants and Spike Mutations vs Convalescent Plasma”

79 (<https://covdb.stanford.edu/page/susceptibility-data/#:~:text=Table%202.->
80 [https://covdb.stanford.edu/page/susceptibility-](https://covdb.stanford.edu/page/susceptibility-data/#:~:text=Table%202.-)
81 [Table%203.%20Virus](https://covdb.stanford.edu/page/susceptibility-data/#table.2.virus.variants.and.spike.mutations.vs.convalescent.plasma)) and “Virus Variants and Spike Mutations vs Plasma from Vaccinated Persons”
82 (<https://covdb.stanford.edu/page/susceptibility->
83 [data/#table.2.virus.variants.and.spike.mutations.vs.convalescent.plasma](https://covdb.stanford.edu/page/susceptibility-data/#table.2.virus.variants.and.spike.mutations.vs.convalescent.plasma)) report aggregate data
84 from only 6 studies, and do not dissect the infecting sublineages, nor the different heterologous or
85 homologous vaccination schemes, nor the time from infection/vaccine to neutralization assay.
86 Consequently, a more in-depth analysis is needed to better stratify the populations.

87

88 Methods

89 On December 22, 2021, we searched PubMed, medRxiv and bioRxiv for research investigating the
90 efficacy of COVID19 convalescent plasma (either from vaccinated or unvaccinated donors) against
91 SARS-CoV-2 VOC Omicron. In unvaccinated patients, convalescence was annotated according to
92 infecting sublineage (unspecified, D614G wild-type, VOC Alpha, VOC Beta or VOC Delta). Given the
93 heterologous immunity that develops after vaccination in convalescents, the infecting lineage was
94 not annotated in vaccine recipients. In vaccinees, strata were created for uninfected, 1 dose, 2
95 homologous doses, 3 homologous doses, or heterologous combinations.

96

97 Results

98 Figure 1 shows the PRISMA flowchart for this study. Our literature search identified 22 studies, that
99 were then manually mined for relevant details.

100 Given the urgency to assess efficacy against the upcoming VOC Omicron, most studies (with a few
101 exceptions [21,30]) relied over Omicron pseudovirus development and neutralization assays, which,
102 as opposed to live authentic virus, are scalable, do not require BSL-3 facilities, and provide results in
103 less than 1 week.

104 Table 1 shows that CCP collected from unvaccinated convalescents (regardless of the infecting
105 lineage) harbors very low or no neutralizing activity against Omicron, and are hence clinically
106 useless.

107 Table 2 shows that CCP from vaccinees that have not been previously or later infected has very low
108 nAb content against Omicron. On the other hand, CCP collected from vaccinated convalescents is
109 generally high in nAb content against Omicron, regardless of the order of events
110 (infection/vaccination vs. vaccination/breakthrough infection [31]), of the infecting sublineage, and
111 of the number of vaccine doses.

112

113 Discussion

114 Although nAb titers correlate with vaccine efficacy [32,33], it is important to keep in mind that SARS-
115 CoV-2 binding non-neutralizing antibodies can similarly provide protection via Fc-mediated functions
116 [34,35]. However, these are harder to measure in the laboratory and no automated assay exist for
117 use in clinical laboratories. Hence, whereas the presence of a high nAb titer in CCP is evidence for
118 antibody effectiveness *in vitro*, the absence of nAb titer does not imply lack of protection *in vivo*
119 where Fc effects mediate protection by other mechanisms such as ADCC, complement activation and

120 phagocytosis. That said, it is always preferable to use CCP with a high nAb titer since that is positive
121 correlate for antiviral activity and there is now strong clinical evidence that such titers correlate with
122 efficacy in clinical trials [25,26].

123 This systematic review provides strong evidence that CCP from unvaccinated donors is unlikely to be
124 effective against Omicron. On the contrary, despite the huge heterogeneity of vaccine schedules,
125 CCP from vaccinated COVID-19 convalescent individuals consistently harbors high nAb titers against
126 Omicron if collected up to 6 months since last event (either vaccine dosage or infection).
127 Consequently, prescreening of CCP donors for nAb titers is not necessary, and qualification of CCP
128 units remains advisable only within clinical trials. A more objective way to assess previous infection
129 would be measuring anti-nucleocapsid (N) antibodies, but unfortunately these vanish quickly [36,37].
130 Previous symptomatic infection and vaccination can be established by collecting past medical history
131 (PMH) during the donor selection visit, which is cheaper, faster, and more reliable than measuring
132 rapidly declining anti-N antibodies. Although there is no formal evidence for this, it is likely that
133 asymptomatic infection (leading to lower nAb levels) also leads to lower nAb levels after vaccination
134 compared to symptomatic infection, given that disease severity correlates with antibody titer
135 [38,39]: hence those asymptotically infected donors missed by investigating PMH are less likely to
136 be useful.

137 The same reasoning applies to uninfected vaccinees receiving third dose boosts, but several
138 authorities, including FDA, do not allow collection from such donors for CCP therapy on the basis
139 that the convalescent polyclonal and poly-target response is a prerequisite for efficacy and superior
140 to the polyclonal anti-Spike only response of vaccinees. This may be a false premise for recipients of
141 inactivated whole-virus vaccines (e.g., BBIBP-CorV or VLA2001): for BBIBP-CorV, the efficacy against
142 Omicron is largely reduced [40,41], but the impact of boost doses is still unreported at the time of
143 writing. For CoronaVac® (SinoVac), three doses led to 5.1 fold-reduction in nAb titer [41], while for
144 Sputnik V nAb titer moved from a 12-fold reduction at 6-12 months up to a 7-fold reduction at 2-3
145 months after a boost with Sputnik Light [30].

146 Another point to consider is that information on levels after third dose do not currently exceed more
147 than one month of follow-up, while studies on convalescents extend to more than 6 months: to date
148 it seems hence advisable to start from convalescent vaccinees rather than uninfected 3-dose
149 vaccinees. Vaccine schedules with a delayed boost seem to elicit higher and broader nAb levels than
150 the approved, short schedules [42-45], but this remain to be confirmed in larger series.

151 With the increase of Omicron seroprevalence in time, polyclonal intravenous immunoglobulins
152 collected from regular donors could become a more standardized alternative to CCP (see Figure 2),
153 but their efficacy to date (at the peak of the vaccinations campaign) is still 16-fold reduced against
154 Omicron compared to wild-type SARS-CoV-2 [14], and such preparations include only IgG and not
155 IgM and IgA, which have powerful SARS-CoV-2 activity.

156 CCP collection from vaccinated convalescents (regardless of infecting sublineage, vaccine type and
157 number of doses) is likely to achieve high nAb titer against VOC Omicron, and, on the basis of lessons
158 learnt with CCP usage during the first 2 years of the pandemic. Although in ideal situations one
159 would prefer RCT evidence of efficacy against omicron before deployment there is concern that
160 variants are generated so rapidly that by the time such trials commenced this variant could be
161 replaced for another. Given the success of CCP in 2 outpatient RCTs reducing hospitalization [25,26]
162 and the loss of major mAb therapies due to Omicron antigenic changes, the high titers in CCP
163 collected from vaccinated convalescents provides an immediate option for COVID-19, especially in
164 resource poor areas. Given the reduced hospitalization rate with Omicron compared to Delta

165 [46,47], it is even more relevant to identify patient subsets at risk of progression in order to minimize
166 the number needed to treat to prevent a single hospitalization: moving from the same criteria used
167 for mAb therapies while using the same (now unused) in-hospital facilities seems a logical approach.
168 We declare we have no conflict of interest related to this manuscript.

169
170
171
172

Table 1

Efficacy of CCP collected from unvaccinated COVID19 survivors, infected from different SARS-CoV-2 VOC, against VOC Omicron. Efficacy is reported as ED₅₀/IC₅₀ or fold-reductions (FR) compared to wild-type D614G lineages (e.g. USA-WA1/2020) at different time points since onset of symptoms or positivity, expressed in days (d) or months (m). BAU: binding arbitrary unit. LOD: limit of dilution.

unspecified	convalescents from VOC				ref
	D614G	Alpha	Beta	Delta	
	no activity @ 1.5 and 12m				Gruell [48]
	ID ₅₀ < 135 @ 1m				Liu [13]
	21 FR, all < LOD (1:20)				Aggarwal [14]
		47 FR		17 FR	Ikemura [8]
	80 FR @ 2m				Hoffman [49]
	BAU/ml reduced from 3x10 ³ to 8x10 ² at 7-25 days (n = 27)				Schubert [11]
none at 6m and 12m (36 pts)					Planas [12]
58 FR @ 1.3m 32 FR @ 6.2m					Schmidt [50]
	ED ₅₀ 68 (10.6 FR @ 1 mo), 65 (5.1 FR @ 3 mo)				Zhang [51]
		IC ₅₀ < 1:16 in 0/10 pts	IC ₅₀ < 1:16 in 7/8 pts	IC ₅₀ < 1:16 in 6/7 pts	Rosler [15]
17 FR					Zhao [41]
	none (2/9 of ICU and 1/9 of hospitalized above cutoff)			none (0/12)	Zeng [17]
	40 FR (IC ₅₀ 23.4 IU/ml) @ 1m or 4m				Sheward [18]
				28.9 FR	Lechmere [31]
none in 73.3%					Carreno [21]
	15 FR @ 1 m 4.4 FR @ 6 m				Zou [52]
	2/20 pts, 2.3-70.1 FR @	2/5 pts, 2.3-70.1 FR	2/2 pts, 2.3-70.1 FR @ 1m	15/17 pts, 22.1-74.4 FR @ 1m	Lusvarghi [53]

174
175
176
177
178
179

Table 2


Efficacy against VOC Omicron of convalescent plasma collected from vaccinated donors, either infected (either before, between or after vaccination with 1 or more homologous or heterologous doses) or uninfected (with 3 homologous or heterologous doses), reported as NT₅₀/ED₅₀/IC₅₀ (dilution factors that yields 50% neutralization of SARS-CoV-2) or fold-reduction (FR) in nAb titers compared to wild-type D614G lineage. Time after last event (infection or vaccination) is reported when available from the original source. The single reference for CoronaVax and Sputnik V are both discussed within the text for space constraints.

BNT162b2/tozinameran (Comirnaty®) (Pfizer/BioNtech)					mRNA-1273/elasomeran (Spikevax®) (Moderna)					AZD1222 / ChAdOx1 (Vaxzevria®, Covishield®) (AstraZeneca)				JNJ-78436735/ Ad26.COV2.S® (J&J/Janssen)		ref
2 doses	3 doses	convalescent + 1 dose	convalescent + 2 doses	convalescent + 3 doses	2 doses	3 doses	2 doses + BNT162b 2	2 doses + infection	3 doses + infection	2 doses	2 dose + infection	1 dose + BNT162 b2	1 dose + 2 BNT162bd oses	1 dose	1 dose + BNT162 b2	
11.4 FR @ 6 m	10 at 0.5 m, (8 FR); 0 @ 3m (20 FR)		32.8-FR @ 1-7m		0 (20 FR compared to Delta) @ 6m		22.7 FR @ 0.5m 20 FR @ 6m					10 FR compared to Delta @ 6m	27.1 FR compared to Delta @ 0.5m			Wilhelm [4]
>6.0FR @ 1m	>4.1 FR @ 1m	ID ₅₀ 1,549 @ 1m			>6.0FR @ 1m	>4.1FR @ 1m										Gruell [48]
														ID ₅₀ < 153 @ 1m		Liu [13]
			17.9-26.6 FR					17.9-26.6 FR								Aggarwal [14]
					27 FR @ 3m											Ikemura [8]
34 FR @ 3m						8 FR @ 1m						14 FR @ 1m				Hoffman [49]
			4.5 FR @ 12-							4.5 FR @ 12-						Lechmere [31]

			22d after Delta BTI							22d Delta BTI					
BAU/ml reduced from 3×10^3 to 8×10^2 @ 7-25d (n = 27)	BAU/ml minimally reduced @ 5-49d													BAU/ml minimally reduced @ 5-49d	Schubert [11]
none @ 5m	ED ₅₀ of 1050 @ 1m	ED ₅₀ Of 1598 @ 1m							none @ 5m						Planas [12]
127 FR @ 1.2m 27 FR @ 5m	NT ₅₀ 3871 @ 1m		NT ₅₀ 8106 (154 folds increase compared to prevaccination)		127 FR @ 1.2m 27 FR @ 5m		NT ₅₀ 3871 @ 1m							NT ₅₀ < 25 @ ~1m and 43 @ 5m	Schmidt [50]
	22 FR @ 10-60 d	22 FR @ 10-60 d													Cele [6]
					49-84 FR @ 1m	4.2-6.5 FR @ 2w after 50 µg boost		? in 2 pts infected between dose 2 and 3							Doria-Rose [55]
IC ₅₀ < 1:16 in 11/20 pts		IC ₅₀ < 1:16 in 1/5 pts vaccinated first			IC ₅₀ < 1:16 in 9/10 pts				IC ₅₀ < 1:16 in 20/20 pts		IC ₅₀ > 1:16 in 7/20 pts				Rossier [15]

182 **Figure 1**

183 PRISMA flowchart for the current study.




184

185 **Figure 2**

186 Simplified representation of the evolution of nAb-based therapeutics along the course of a pandemic.

187



188

189 References

- 190 1. Yeh, T.-Y.; Contreras, G.P. Tajima D test accurately forecasts Omicron / COVID-19 outbreak.
191 **2021**, 10.1101/2021.12.02.21267185 %J medRxiv, 2021.2012.2002.21267185,
192 doi:10.1101/2021.12.02.21267185 %J medRxiv.
- 193 2. Ahmed, S.F.; Quadeer, A.A.; McKay, M. SARS-CoV-2 T cell responses are expected to remain
194 robust against Omicron. **2021**, 10.1101/2021.12.12.472315 %J bioRxiv,
195 2021.2012.2012.472315, doi:10.1101/2021.12.12.472315 %J bioRxiv.
- 196 3. Bernasconi, A.; Pinoli, P.; Al Khalaf, R.; Alfonsi, T.; Canakoglu, A.; Cilibrasi, L.; Ceri, S. Report
197 on Omicron Spike mutations on epitopes and immunological/epidemiological/kinetics
198 effects from literature. Available online: [https://virological.org/t/report-on-omicron-spike-](https://virological.org/t/report-on-omicron-spike-mutations-on-epitopes-and-immunological-epidemiological-kinetics-effects-from-literature/770)
199 [mutations-on-epitopes-and-immunological-epidemiological-kinetics-effects-from-](https://virological.org/t/report-on-omicron-spike-mutations-on-epitopes-and-immunological-epidemiological-kinetics-effects-from-literature/770)
200 [literature/770](https://virological.org/t/report-on-omicron-spike-mutations-on-epitopes-and-immunological-epidemiological-kinetics-effects-from-literature/770) (accessed on
201 4. Wilhelm, A.; Widera, M.; Grikscheit, K.; Toptan, T.; Schenk, B.; Pallas, C.; Metzler, M.;
202 Kohmer, N.; Hoehl, S.; Helfritz, F.A., et al. Reduced Neutralization of SARS-CoV-2 Omicron
203 Variant by Vaccine Sera and monoclonal antibodies. **2021**, 10.1101/2021.12.07.21267432 %J
204 medRxiv, 2021.2012.2007.21267432, doi:10.1101/2021.12.07.21267432 %J medRxiv.
- 205 5. Cao, Y.R.; Wang, J.; Jian, F.; Xiao, T.; Song, W.; Yisimayi, A.; Huang, W.; Li, Q.; Wang, P.; An,
206 R., et al. B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse
207 epitopes. **2021**, 10.1101/2021.12.07.470392 %J bioRxiv, 2021.2012.2007.470392,
208 doi:10.1101/2021.12.07.470392 %J bioRxiv.
- 209 6. Cele, S.; Jackson, L.; Khan, K.; Khoury, D.S.; Moyo-Gwete, T.; Tegally, H.; Scheepers, C.;
210 Amoako, D.; Karim, F.; Bernstein, M., et al. SARS-CoV-2 Omicron has extensive but
211 incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for
212 infection. **2021**, 10.1101/2021.12.08.21267417 %J medRxiv, 2021.2012.2008.21267417,
213 doi:10.1101/2021.12.08.21267417 %J medRxiv.
- 214 7. Lu, L.; Mok, B.; Chen, L.; Chan, J.; Tsang, O.; Lam, B.; Chuang, V.; Chu, A.; Chan, A.; Ip, J., et al.
215 Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine
216 recipients. **2021**, 10.1101/2021.12.13.21267668 %J medRxiv, 2021.2012.2013.21267668,
217 doi:10.1101/2021.12.13.21267668 %J medRxiv.
- 218 8. Ikemura, N.; Hoshino, A.; Higuchi, Y.; Tamishishi, S.; Inaba, T.; Matoba, S. SARS-CoV-2
219 Omicron variant escapes neutralization by vaccinated and convalescent sera and therapeutic
220 monoclonal antibodies. **2021**, 10.1101/2021.12.13.21267761 %J medRxiv,
221 2021.2012.2013.21267761, doi:10.1101/2021.12.13.21267761 %J medRxiv.
- 222 9. Basile, K.; Rockett, R.J.; McPhie, K.; Fennell, M.; Johnson-Mackinnon, J.; Agius, J.; Fong, W.;
223 Rahman, H.; Ko, D.; Donavan, L., et al. Improved neutralization of the SARS-CoV-2 Omicron
224 variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting. **2021**,
225 10.1101/2021.12.12.472252 %J bioRxiv, 2021.2012.2012.472252,
226 doi:10.1101/2021.12.12.472252 %J bioRxiv.
- 227 10. Garcia-Beltran, W.F.; St Denis, K.J.; Hoelzemer, A.; Lam, E.C.; Nitido, A.D.; Sheehan, M.L.;
228 Berrios, C.; Ofoman, O.; Chang, C.C.; Hauser, B.M., et al. mRNA-based COVID-19 vaccine
229 boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. **2021**,
230 10.1101/2021.12.14.21267755 %J medRxiv, 2021.2012.2014.21267755,
231 doi:10.1101/2021.12.14.21267755 %J medRxiv.
- 232 11. Schubert, M.; Bertoglio, F.; Steinke, S.; Heine, P.A.; Ynga-Durand, M.A.; Zuo, F.; Du, L.; Korn,
233 J.; Milosevic, M.; Wenzel, E.V., et al. Human serum from SARS-CoV-2 vaccinated and COVID-
234 19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant in comparison
235 to the original Wuhan strain and the Beta and Delta variants. **2021**,
236 10.1101/2021.12.10.21267523 %J medRxiv, 2021.2012.2010.21267523,
237 doi:10.1101/2021.12.10.21267523 %J medRxiv.
- 238 12. Planas, D.; Saunders, N.; Maes, P.; Benhassine, F.G.; Planchais, C.; Porrot, F.; Staropoli, I.;
239 Lemoine, F.; Pere, H.; Veyer, D., et al. Considerable escape of SARS-CoV-2 variant Omicron to

- 240 antibody neutralization. **2021**, 10.1101/2021.12.14.472630 %J bioRxiv,
241 2021.2012.2014.472630, doi:10.1101/2021.12.14.472630 %J bioRxiv.
- 242 13. Liu, L.; Iketani, S.; Guo, Y.; Chan, J.F.-W.; Wang, M.; Liu, L.; Luo, Y.; Chu, H.; Huang, Y.; Nair,
243 M.S., et al. Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2.
244 **2021**, 10.1101/2021.12.14.472719 %J bioRxiv, 2021.2012.2014.472719,
245 doi:10.1101/2021.12.14.472719 %J bioRxiv.
- 246 14. Aggarwal, A.; Ospina Stella, A.; Walker, G.; Akerman, A.; Milogiannakis, V.; Hoppe, A.C.;
247 Mathivanan, V.; Fichter, C.; McAllery, S.; Amatayakul-Chantler, S., et al. SARS-CoV-2
248 Omicron: reduction of potent humoral responses and resistance to clinical
249 immunotherapeutics relative to viral variants of concern. **2021**,
250 10.1101/2021.12.14.21267772 %J medRxiv, 2021.2012.2014.21267772,
251 doi:10.1101/2021.12.14.21267772 %J medRxiv.
- 252 15. Rössler, A.; Riepler, L.; Bante, D.; Laer, D.v.; Kimpel, J. SARS-CoV-2 B.1.1.529 variant
253 (Omicron) evades neutralization by sera from vaccinated and convalescent individuals. **2021**,
254 10.1101/2021.12.08.21267491 %J medRxiv, 2021.2012.2008.21267491,
255 doi:10.1101/2021.12.08.21267491 %J medRxiv.
- 256 16. Dejnirattisai, W.; Shaw, R.H.; Supasa, P.; Liu, C.; Stuart, A.S.; Pollard, A.J.; Liu, X.; Lambe, T.;
257 Crook, D.; Stuart, D.I., et al. Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529
258 variant by post-immunisation serum. **2021**, 10.1101/2021.12.10.21267534 %J medRxiv,
259 2021.2012.2010.21267534, doi:10.1101/2021.12.10.21267534 %J medRxiv.
- 260 17. Cong, Z.; Evans, J.P.; Qu, P.; Faraone, J.; Zheng, Y.-M.; Carlin, C.; Bednash, J.S.; Zhou, T.;
261 Lozanski, G.; Mallampalli, R., et al. Neutralization and Stability of SARS-CoV-2 Omicron
262 Variant. **2021**, 10.1101/2021.12.16.472934 %J bioRxiv, 2021.2012.2016.472934,
263 doi:10.1101/2021.12.16.472934 %J bioRxiv.
- 264 18. Sheward, D.J.; Kim, C.; Ehling, R.A.; Pankow, A.; Castro Dopico, X.; Martin, D.P.; Reddy, S.T.;
265 Dillner, J.; Karlsson Hedestam, G.B.; Albert, J., et al. Variable loss of antibody potency against
266 SARS-CoV-2 B.1.1.529 (Omicron). **2021**, 10.1101/2021.12.19.473354 %J bioRxiv,
267 2021.2012.2019.473354, doi:10.1101/2021.12.19.473354 %J bioRxiv.
- 268 19. Jacobsen, H.; Strengert, M.; Maass, H.; Ynga Durand, M.A.; Kessel, B.; Harries, M.; Rand, U.;
269 Abassi, L.; Kim, Y.; Lueddecke, T., et al. Diminished neutralization responses towards SARS-
270 CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations. **2021**,
271 10.1101/2021.12.21.21267898 %J medRxiv, 2021.2012.2021.21267898,
272 doi:10.1101/2021.12.21.21267898 %J medRxiv.
- 273 20. VanBlargan, L.A.; Errico, J.M.; Halfmann, P.; Zost, S.J.; Crowe, J.E.; Purcell, L.A.; Kawaoka, Y.;
274 Corti, D.; Fremont, D.H.; Diamond, M. An infectious SARS-CoV-2 B.1.1.529 Omicron virus
275 escapes neutralization by several therapeutic monoclonal antibodies. **2021**,
276 10.1101/2021.12.15.472828 %J bioRxiv, 2021.2012.2015.472828,
277 doi:10.1101/2021.12.15.472828 %J bioRxiv.
- 278 21. Carreno, J.M.; Alshammary, H.; Tcheou, J.; Singh, G.; Raskin, A.; Kawabata, H.; Sominsky, L.;
279 Clark, J.; Adelsberg, D.C.; Bielak, D., et al. Activity of convalescent and vaccine serum against
280 a B.1.1.529 variant SARS-CoV-2 isolate. **2021**, 10.1101/2021.12.20.21268134 %J medRxiv,
281 2021.2012.2020.21268134, doi:10.1101/2021.12.20.21268134 %J medRxiv.
- 282 22. Therapeutic Goods Administration. Australian Product Information – XEVUDY (Sotrovimab)
283 Concentrated Injection solution for infusion. (2021). Accessed on December 22, 2021 at
284 <https://www.tga.gov.au/sites/default/files/xevudy-pi.pdf>.
- 285 23. Rockett, R.J.; Basile, K.; Maddocks, S.; Fong, W.; Agius, J.E.; Johnson-Mackinnon, J.; Arnott,
286 A.; Chandra, S.; Gall, M.; Draper, J.L., et al. RESISTANCE CONFERRING MUTATIONS IN SARS-
287 CoV-2 DELTA FOLLOWING SOTROVIMAB INFUSION. **2021**, 10.1101/2021.12.18.21267628 %J
288 medRxiv, 2021.2012.2018.21267628, doi:10.1101/2021.12.18.21267628 %J medRxiv.
- 289 24. Focosi, D.; Franchini, M.; Pirofski, L.-a.; Burnouf, T.; Paneth, N.; Joyner, M.J.; Casadevall, A.
290 COVID-19 convalescent plasma and randomized clinical trials: rebuilding confidence by

- 291 explaining failures and finding signals of efficacy. **2021**, 10.1101/2021.09.07.21263194 %J
292 medRxiv, 2021.2009.2007.21263194, doi:10.1101/2021.09.07.21263194 %J medRxiv.
- 293 25. Libster, R.; Pérez Marc, G.; Wappner, D.; Coviello, S.; Bianchi, A.; Braem, V.; Esteban, I.;
294 Caballero, M.T.; Wood, C.; Berrueta, M., et al. Early High-Titer Plasma Therapy to Prevent
295 Severe Covid-19 in Older Adults. *N Engl J Med* **2021**, *384*, 610-618,
296 doi:10.1056/NEJMoa2033700.
- 297 26. Sullivan, D.; Gebo, K.; Shoham, S.; Bloch, E.; Lau, B.; Shenoy, A.; Mosnaim, G.; Gniadek, T.;
298 Fukuta, Y.; Patel, B., et al. Randomized Controlled Trial of Early Outpatient COVID-19
299 Treatment with High-Titer Convalescent Plasma. *medRxiv* **2021**.
- 300 27. Vickers, M.A.; Sariol, A.; Leon, J.; Ehlers, A.; Locher, A.V.; Dubay, K.A.; Collins, L.; Voss, D.;
301 Odle, A.E.; Holida, M., et al. Exponential increase in neutralizing and spike specific antibodies
302 following vaccination of COVID-19 convalescent plasma donors. *Transfusion* **2021**, *61*, 2099-
303 2106, doi:10.1111/trf.16401.
- 304 28. Schmidt, F.; Weisblum, Y.; Rutkowska, M.; Poston, D.; Da Silva, J.; Zhang, F.; Bednarski, E.;
305 Cho, A.; Schaefer-Babajew, D.J.; Gaebler, C., et al. High genetic barrier to SARS-CoV-2
306 polyclonal neutralizing antibody escape. *Nature* **2021**, 10.1038/s41586-021-04005-0,
307 doi:10.1038/s41586-021-04005-0.
- 308 29. Germanio, C.D.; Simmons, G.; Thorbrogger, C.; Martinelli, R.; Stone, M.; Gniadek, T.; Busch,
309 M.P. Vaccination of COVID-19 Convalescent Plasma Donors Increases Binding and
310 Neutralizing Antibodies Against SARS-CoV-2 Variants. **2021**, 10.1101/2021.10.28.21265622
311 %J medRxiv, 2021.2010.2028.21265622, doi:10.1101/2021.10.28.21265622 %J medRxiv.
- 312 30. Dolzhikova, I.V.; Iliukhina, A.A.; Kovyrshina, A.V.; Kuzina, A.V.; Gushchin, V.A.; Siniavin, A.E.;
313 Pochtovyi, A.A.; Shidlovskaya, E.V.; Kuznetsova, N.A.; Megeryan, M.M., et al. Sputnik Light
314 booster after Sputnik V vaccination induces robust neutralizing antibody response to
315 B.1.1.529 (Omicron) SARS-CoV-2 variant. **2021**, 10.1101/2021.12.17.21267976 %J medRxiv,
316 2021.2012.2017.21267976, doi:10.1101/2021.12.17.21267976 %J medRxiv.
- 317 31. Lechmere, T.; Snell, L.B.; Graham, C.; Seow, J.; Shalim, Z.A.; Charalampous, T.; Alcolea-
318 Medina, A.; Batra, R.; Nebbia, G.; Edgeworth, J.D., et al. Broad neutralization of SARS-CoV-2
319 variants, including omicron, following breakthrough infection with delta in COVID-19
320 vaccinated individuals. **2021**, 10.1101/2021.12.01.21266982 %J medRxiv,
321 2021.2012.2001.21266982, doi:10.1101/2021.12.01.21266982 %J medRxiv.
- 322 32. Khoury, D.S.; Cromer, D.; Reynaldi, A.; Schlub, T.E.; Wheatley, A.K.; Juno, J.A.; Subbarao, K.;
323 Kent, S.J.; Triccas, J.A.; Davenport, M.P. Neutralizing antibody levels are highly predictive of
324 immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* **2021**, *27*, 1205-1211,
325 doi:10.1038/s41591-021-01377-8.
- 326 33. Feng, S.; Phillips, D.J.; White, T.; Sayal, H.; Aley, P.K.; Bibi, S.; Dold, C.; Fuskova, M.; Gilbert,
327 S.C.; Hirsch, I., et al. Correlates of protection against symptomatic and asymptomatic SARS-
328 CoV-2 infection. *Nat Med* **2021**, *27*, 2032-2040, doi:10.1038/s41591-021-01540-1.
- 329 34. Gilbert, P.B.; Montefiori, D.C.; McDermott, A.B.; Fong, Y.; Benkeser, D.; Deng, W.; Zhou, H.;
330 Houchens, C.R.; Martins, K.; Jayashankar, L., et al. Immune correlates analysis of the mRNA-
331 1273 COVID-19 vaccine efficacy clinical trial. *Science* **2021**, eab3435.
- 332 35. Earle, K.A.; Ambrosino, D.M.; Fiore-Gartland, A.; Goldblatt, D.; Gilbert, P.B.; Siber, G.R.; Dull,
333 P.; Plotkin, S.A. Evidence for antibody as a protective correlate for COVID-19 vaccines.
334 *Vaccine* **2021**, *39*, 4423-4428, doi:10.1016/j.vaccine.2021.05.063.
- 335 36. Krutikov, M.; Palmer, T.; Tut, G.; Fuller, C.; Azmi, B.; Giddings, R.; Shrotri, M.; Kaur, N.; Sylla,
336 P.; Lancaster, T., et al. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid
337 antibodies in staff and residents of long-term care facilities over the first year of the
338 pandemic (VIVALDI study): prospective cohort study in England. *The Lancet Healthy*
339 *Longevity* **2021**, [https://doi.org/10.1016/S2666-7568\(21\)00282-8](https://doi.org/10.1016/S2666-7568(21)00282-8),
340 doi:[https://doi.org/10.1016/S2666-7568\(21\)00282-8](https://doi.org/10.1016/S2666-7568(21)00282-8).

- 341 37. Amjadi, M.F.; Adyniec, R.R.; Gupta, S.; Bashar, S.J.; Mergaert, A.M.; Braun, K.M.; Moreno,
342 G.K.; O'Connor, D.H.; Friedrich, T.C.; Safdar, N., et al. Anti-membrane and anti-spike
343 antibodies are long-lasting and together discriminate between past COVID-19 infection and
344 vaccination. **2021**, 10.1101/2021.11.02.21265750 %J medRxiv, 2021.2011.2002.21265750,
345 doi:10.1101/2021.11.02.21265750 %J medRxiv.
- 346 38. Klein, S.; Pekosz, A.; Park, H.-S.; Ursin, R.; Shapiro, J.; Benner, S.; Littlefield, K.; Kumar, S.;
347 Naik, H.M.; Betenbaugh, M., et al. Sex, age, and hospitalization drive antibody responses in a
348 COVID-19 convalescent plasma donor population. Available online:
349 <https://www.medrxiv.org/content/medrxiv/early/2020/06/28/2020.06.26.20139063.full.pdf>
350 (accessed on Feb 5, 2021).
- 351 39. Focosi, D.; Franchini, M. Clinical predictors of SARS-CoV-2 neutralizing antibody titers in
352 COVID-19 convalescents: Implications for convalescent plasma donor recruitment. *European*
353 *journal of haematology* **2021**, 107, 24-28, doi:10.1111/ejh.13630.
- 354 40. Yu, X.; Wei, D.; Xu, W.; Li, Y.; Li, X.; Zhang, X.-x.; Qu, J.; Yang, Z.; Chen, E. Pseudotyped SARS-
355 CoV-2 Omicron variant exhibits significant escape from neutralization induced by a third
356 booster dose of vaccination. **2021**, 10.1101/2021.12.17.21267961 %J medRxiv,
357 2021.2012.2017.21267961, doi:10.1101/2021.12.17.21267961 %J medRxiv.
- 358 41. Zhao, X.; Li, D.; Ruan, W.; Zhang, R.; Zheng, A.; Qiao, S.; Zheng, X.; Zhao, Y.; Chen, Z.; Dai, L.,
359 et al. Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and protein
360 subunit vaccines and the convalescents. **2021**, 10.1101/2021.12.16.472391 %J bioRxiv,
361 2021.2012.2016.472391, doi:10.1101/2021.12.16.472391 %J bioRxiv.
- 362 42. Chatterjee, D.; Tauzin, A.; Marchitto, L.; Gong, S.Y.; Boutin, M.; Bourassa, C.; Beaudoin-
363 Bussieres, G.; Bo, Y.; Ding, S.; Laumaea, A., et al. SARS-CoV-2 Omicron Spike recognition by
364 plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval
365 between doses. **2021**, 10.1101/2021.12.21.473679 %J bioRxiv, 2021.2012.2021.473679,
366 doi:10.1101/2021.12.21.473679 %J bioRxiv.
- 367 43. Grunau, B.; Goldfarb, D.M.; Asamoah-Boaheng, M.; Golding, L.; Kirkham, T.L.; Demers, P.A.;
368 Lavoie, P.M. Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals. *Jama*
369 **2021**, 10.1001/jama.2021.21921, doi:10.1001/jama.2021.21921.
- 370 44. Tauzin, A.; Nayrac, M.; Benlarbi, M.; Gong, S.Y.; Gasser, R.; Beaudoin-Bussieres, G.; Brassard,
371 N.; Laumaea, A.; Vezina, D.; Prevost, J., et al. A single BNT162b2 mRNA dose elicits
372 antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell
373 responses. *medRxiv [Preprint]* **2021**, 10.1101/2021.03.18.435972 %J bioRxiv,
374 2021.2003.2018.435972, doi:10.1101/2021.03.18.435972 %J bioRxiv.
- 375 45. Skowronski, D.M.; Setayeshgar, S.; Febriani, Y.; Ouakki, M.; Zou, M.; Talbot, D.; Prystajecy,
376 N.; Tyson, J.R.; Gilca, R.; Brousseau, N., et al. Two-dose SARS-CoV-2 vaccine effectiveness
377 with mixed schedules and extended dosing intervals: test-negative design studies from
378 British Columbia and Quebec, Canada. **2021**, 10.1101/2021.10.26.21265397 %J medRxiv,
379 2021.2010.2026.21265397, doi:10.1101/2021.10.26.21265397 %J medRxiv.
- 380 46. MRC Centre for Global Infectious Disease Analysis. Report 50 - Hospitalisation risk for
381 Omicron cases in England. Accessed online at [https://www.imperial.ac.uk/media/imperial-](https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2021-12-22-COVID19-Report-50.pdf)
382 [college/medicine/mrc-gida/2021-12-22-COVID19-Report-50.pdf](https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2021-12-22-COVID19-Report-50.pdf) on December 23, 2021.
383 Available online: (accessed on
- 384 47. Wolter, N.; Jassat, W.; Walaza, S.; Welch, R.; Moultrie, H.; Groome, M.; Amoako, D.G.;
385 Everatt, J.; Bhiman, J.N.; Scheepers, C., et al. Early assessment of the clinical severity of the
386 SARS-CoV-2 Omicron variant in South Africa. **2021**, 10.1101/2021.12.21.21268116 %J
387 medRxiv, 2021.2012.2021.21268116, doi:10.1101/2021.12.21.21268116 %J medRxiv.
- 388 48. Gruell, H.; Vanshylla, K.; Tober-Lau, P.; Hillus, D.; Schommers, P.; Lehmann, C.; Kurth, F.;
389 Sander, L.E.; Klein, F. mRNA booster immunization elicits potent neutralizing serum activity
390 against the SARS-CoV-2 Omicron variant. **2021**, 10.1101/2021.12.14.21267769 %J medRxiv,
391 2021.2012.2014.21267769, doi:10.1101/2021.12.14.21267769 %J medRxiv.

- 392 49. Hoffmann, M.; Krüger, N.; Schulz, S.; Cossmann, A.; Rocha, C.; Kempf, A.; Nehlmeier, I.;
393 Graichen, L.; Moldenhauer, A.-S.; Winkler, M.S., et al. The Omicron variant is highly resistant
394 against antibody-mediated neutralization - implications for control of the COVID-19
395 pandemic. **2021**, 10.1101/2021.12.12.472286 %J bioRxiv, 2021.2012.2012.472286,
396 doi:10.1101/2021.12.12.472286 %J bioRxiv.
- 397 50. Schmidt, F.; Muecksch, F.; Weisblum, Y.; Da Silva, J.; Bednarski, E.; Cho, A.; Wang, Z.;
398 Gaebler, C.; Caskey, M.; Nussenzweig, M., et al. Plasma neutralization properties of the
399 SARS-CoV-2 Omicron variant. **2021**, 10.1101/2021.12.12.21267646 %J medRxiv,
400 2021.2012.2012.21267646, doi:10.1101/2021.12.12.21267646 %J medRxiv.
- 401 51. Zhang, L.; Li, Q.; Liang, Z.; Li, T.; Liu, S.; Cui, Q.; Nie, J.; Wu, Q.; Qu, X.; Huang, W., et al. The
402 significant immune escape of pseudotyped SARS-CoV-2 Variant Omicron. *Emerging microbes*
403 & *infections* **2021**, 10.1080/22221751.2021.2017757, 1-11,
404 doi:10.1080/22221751.2021.2017757.
- 405 52. Zou, j.; Xia, H.; Xie, X.; Kurhade, C.; Machado, R.R.; Weaver, S.C.; Ren, P.; Shi, P.-Y.
406 Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. **2021**,
407 10.1101/2021.12.20.473584 %J bioRxiv, 2021.2012.2020.473584,
408 doi:10.1101/2021.12.20.473584 %J bioRxiv.
- 409 53. Lusvardi, S.; Pollett, S.D.; Neerukonda, S.N.; WANG, W.; Wang, R.; Vassell, R.; Epsi, N.J.;
410 Fries, A.C.; Agan, B.K.; Lindholm, D.A., et al. SARS-CoV-2 Omicron neutralization by
411 therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster. **2021**,
412 10.1101/2021.12.22.473880 %J bioRxiv, 2021.2012.2022.473880,
413 doi:10.1101/2021.12.22.473880 %J bioRxiv.
- 414 54. Syed, A.M.; Ciling, A.; Khalid, M.M.; Sreekumar, B.; Kumar, G.R.; Silva, I.; Milbes, B.; Kojima,
415 N.; Hess, V.; Shacreaw, M., et al. Omicron mutations enhance infectivity and reduce
416 antibody neutralization of SARS-CoV-2 virus-like particles. **2021**,
417 10.1101/2021.12.20.21268048 %J medRxiv, 2021.2012.2020.21268048,
418 doi:10.1101/2021.12.20.21268048 %J medRxiv.
- 419 55. Doria-Rose, N.; Shen, X.; Schmidt, S.D.; O'Dell, S.; McDanal, C.; Feng, W.; Tong, J.; Eaton, A.;
420 Magliano, M.; Tang, H., et al. Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron
421 Escape from Neutralizing Antibodies. **2021**, 10.1101/2021.12.15.21267805 %J medRxiv,
422 2021.2012.2015.21267805, doi:10.1101/2021.12.15.21267805 %J medRxiv.
- 423 56. Edara, V.-V.; Manning, K.E.; Ellis, M.; Lai, L.; Moore, K.M.; Foster, S.L.; Floyd, K.; Davis-
424 Gardner, M.E.; Mantus, G.; Nyhoff, L.E., et al. mRNA-1273 and BNT162b2 mRNA vaccines
425 have reduced neutralizing activity against the SARS-CoV-2 Omicron variant. **2021**,
426 10.1101/2021.12.20.473557 %J bioRxiv, 2021.2012.2020.473557,
427 doi:10.1101/2021.12.20.473557 %J bioRxiv.

428